Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD

Chest. 2002 May;121(5):1449-55. doi: 10.1378/chest.121.5.1449.


Background: Although exacerbations are the main cause of medical visits and hospitalizations of patients with chronic bronchitis and COPD, little information is available on the costs of their management.

Objective: This study attempted to determine the total direct costs derived from the management of exacerbations of chronic bronchitis and COPD in an ambulatory setting.

Method: A total of 2,414 patients with exacerbated chronic bronchitis and COPD were recruited from 268 general practices located throughout Spain. Patients were followed up for 1 month.

Results: A total of 507 patients (21%) relapsed; of these, 161 patients (31.7%) required attention in emergency departments and 84 patients (16.5%) were admitted to the hospital. The total direct mean cost of all exacerbations was $159; patients who were hospitalized generated 58% of the total cost. Cost per failure was $477.50, and failures were responsible for an added mean cost of $100.30/exacerbation. Exacerbations of the 1,130 patients with COPD had a mean cost of $141. Sensitivity analysis showed that a 50% reduction in the failure rate (from 21 to 10.5%) would result in a total cost of exacerbation of $107 (33% reduction).

Conclusion: Exacerbations of chronic bronchitis and COPD are costly, but the greatest part of costs derives from therapeutic failures, particularly those that end in hospitalization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Aged
  • Ambulatory Care / economics
  • Bronchitis / economics*
  • Chronic Disease
  • Drug Costs
  • Emergency Service, Hospital / economics
  • Female
  • Health Care Costs*
  • Hospitalization / economics
  • Humans
  • Male
  • Prospective Studies
  • Pulmonary Disease, Chronic Obstructive / economics*
  • Recurrence
  • Spain
  • Treatment Failure